Brinavess (vernakalant hydrochloride)
- Region
- 🇪🇺 EU
- Active substance
- vernakalant hydrochloride
- Company
- Advanz Pharma Limited
- Status
- Authorised
- Therapeutic area
- Atrial Fibrillation
- EU approval
- Wed 01 Sep 2010
- Application
- EMEA/H/C/001215
- ATC
- C01BG11
- Official record
- www.ema.europa.eu
Indication
Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: for non-surgery patients: atrial fibrillation </= 7 days duration; for post-cardiac surgery patients: atrial fibrillation </= 3 days duration.
Regulatory milestones
No milestones recorded in the last year.
Follow Brinavess
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.